Overview

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2020-04-17
Target enrollment:
Participant gender:
Summary
To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Empagliflozin